Government Contracting Compliance & GSA Schedule Support

The contract solicits the supply of biotechnology reagents through existing GSA Schedule or GWAC vehicles, requiring full compliance with the Federal Acquisition Regulation for pricing and delivery terms. All offerings must leverage pre-negotiated, FAR-compliant contractual mechanisms to ensure transparency, affordability, and efficiency in procurement by the National Institutes of Health, specifically the National Institute on Drug Abuse under the Department of Health and Human Services. The NAICS code 325412 confirms the primary focus on pharmaceutical and biological product manufacturing, indicating the need for high-purity, research-grade reagents suitable for scientific and clinical applications. Responses must be submitted by August 13, 2026, and the contract is structured as a subcontract, implying the awardee will fulfill obligations under a prime contract holder rather than directly with the government. Performance is expected to align with federal supply chain standards, though no specific place of performance or set-aside criteria are provided. Compliance with GSA Schedule or GWAC terms is mandatory, ensuring that pricing remains consistent with established federal rates and that delivery timelines meet agency operational needs. The solicitation underscores the importance of proven regulatory adherence and reliable supply chain execution to support critical biomedical research activities.